診療領域

創薬と製薬

標的、分子、カルテと試験の照合。

2 件

創薬と製薬

論文

A generative-AI-designed molecule in a phase 2a IPF trial

Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.

Pharma.AI · Insilico Medicine · rentosertib (ISM001-055)

論文 · 2025事例を読む

創薬と製薬

Matching a cancer chart to trial eligibility

Trial-matching tools read structured fields and sometimes the free-text note to list studies a patient might qualify for. Tempus, Flatiron, and Deep 6 AI are examples of companies that sell a version of this. A research coordinator still checks every criterion against the chart. A match list is not enrollment, and it is not a treatment recommendation.

Tempus · Flatiron · Deep 6 AI

ベンダー · 2025事例を読む